{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:54:56Z","timestamp":1789480496996,"version":"build-2803163510"},"reference-count":86,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T00:00:00Z","timestamp":1326672000000},"content-version":"vor","delay-in-days":2937,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2004,1]]},"abstract":"<jats:p>\n                    The advent of multidrug\u2010resistant gram\u2010positive aerobes such as\n                    <jats:italic>Staphylococcus aureus, Streptococcus pneumoniae<\/jats:italic>\n                    , and the enterococci, which are resistant to \u03b2\u2010lactams, vancomycin, and a host of other commonly used antimicrobials, has complicated our approach to antibiotic therapy. Despite marketing of the first oxazolidinone, linezolid, and the streptogramin combination, quinupristin\u2010dalfopristin, an urgent need exists for more agents to combat these pathogens. Two such agents, the glycopeptide oritavancin (LY333328) and the glycylcycline tigecycline (GAR\u2010936), are in phase III clinical trials. These agents, which require parenteral administration, exhibit substantial in vitro activity against a variety of gram\u2010positive aerobes and anaerobes, including the multidrug\u2010resistant organisms listed previously. Only tigecycline demonstrates useful activity against gram\u2010negative organisms. Combination therapy of these agents with ampicillin or aminoglycosides frequently leads to synergistic in vitro activity against multidrug\u2010resistant staphylococci and streptococci. These agents are also active in a variety of animal models of systemic and localized infections. Few published efficacy and tolerability data are available in humans. If controlled clinical trial data verify these agents' efficacy and tolerability, both drugs should become welcome additions to the available antimicrobials. However, restricting their use to the treatment of infections caused by bacteria resistant to other antimicrobials, especially multidrug\u2010resistant staphylococci and streptococci, may prolong their clinical utility by retarding the development of resistance. Careful surveillance of bacterial sensitivity to these agents should be undertaken to assist clinicians in the decision whether or not to use these agents empirically to treat infections caused by suspected multidrug\u2010resistant gram\u2010positive pathogens.\n                  <\/jats:p>","DOI":"10.1592\/phco.24.1.58.34808","type":"journal-article","created":{"date-parts":[[2004,6,14]],"date-time":"2004-06-14T08:13:28Z","timestamp":1087200808000},"page":"58-68","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Oritavancin and Tigecycline: Investigational Antimicrobials for Multidrug\u2010Resistant Bacteria"],"prefix":"10.1002","volume":"24","author":[{"given":"David R. P.","family":"Guay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,16]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2000.00005.x"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/srin.2001.25624"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.42.091601.142813"},{"issue":"115","key":"e_1_2_1_5_2","first-page":"66","article-title":"Glycopeptide\u2010resistant Staphylococcus aureus","author":"Edmond M","year":"2000","journal-title":"Int J Clin Prac"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06964-1"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80028-X"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.49.575"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867013371716"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2003.tb00628.x"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.2.266"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.5.1370-1374.2000"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1128\/AAC.40.9.2194","article-title":"Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin\u2010resistant enterococci","volume":"40","author":"Nicas TI","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.10.2416"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1128\/AAC.41.2.488","article-title":"In vitro activity and spectrum of LY333328, a novel glycopeptide derivative","volume":"41","author":"Jones RN","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1128\/AAC.41.10.2165","article-title":"In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide","volume":"41","author":"Biavasco F.","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1128\/AAC.42.9.2452","article-title":"In vitro activity of the new glycopeptide LY333328 against multiple\u2010resistant gram\u2010positive isolates","volume":"42","author":"Garcia\u2010Garrote F.","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(01)00355-7"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.1999.11.2.90"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1128\/AAC.40.11.2661","article-title":"Comparative activities of LY333328, a new glycopeptide, against penicillin\u2010susceptible and \u2010resistant pneumococci","volume":"40","author":"Fasola E.","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.2.283"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.3.423"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.35.12.3026-3031.1997"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.5.733"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/41.2.273"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1128\/AAC.42.10.2564","article-title":"Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin\u2010resistant Enterococcus faecium","volume":"42","author":"Baltch AL","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1128\/AAC.43.1.115","article-title":"Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin\u2010resistant Enterococcus faecalis","volume":"43","author":"Saleh\u2010Mghir A.","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(01)00471-X"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1159\/000048552"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02771843"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.3017-3021.2000"},{"key":"e_1_2_1_32_2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1128\/AAC.43.3.717","article-title":"Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin\u2010sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin\u2010intermediate Staphylococcus aureus by time\u2010kill curve methods","volume":"43","author":"Hershberger E.","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.2991-2998.2000"},{"key":"e_1_2_1_34_2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1128\/AAC.41.6.1307","article-title":"Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium","volume":"41","author":"Mercier RC","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.706-709.2001"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2283-2292.2003"},{"key":"e_1_2_1_37_2","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1128\/AAC.43.3.592","article-title":"Synergy of an investigational glycopeptide, LY333328, with once\u2010daily gentamicin against Enterococcus faecium in a multiple\u2010dose, in vitro pharmacodynamic model","volume":"43","author":"Zelenitsky SA","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_38_2","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1128\/AAC.41.11.2573","article-title":"In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combination against vancomycin\u2010resistant Enterococcus faecium","volume":"41","author":"Mercier RC","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_39_2","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1128\/AAC.43.8.1875","article-title":"Moderate\u2010level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci","volume":"43","author":"Arthur M.","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.5.705"},{"key":"e_1_2_1_41_2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.42.4.981","article-title":"Efficacy of LY333328 against experimental methicillin\u2010resistant Staphylococcus aureus endocarditis","volume":"42","author":"Kaatz GW","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.2169-2172.2001"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1700-1706.2003"},{"key":"e_1_2_1_44_2","first-page":"A\u201055","volume-title":"Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 24\u201327, 1998","author":"Chien J.","year":"1998"},{"key":"e_1_2_1_45_2","first-page":"A\u201018","volume-title":"Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 14\u201317, 2003","author":"Fetterly GJ","year":"2003"},{"key":"e_1_2_1_46_2","first-page":"A\u20102193","volume-title":"Program and abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, December 16\u201319, 2001","author":"Rowe PA","year":"2001"},{"key":"e_1_2_1_47_2","volume-title":"Program and abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, December 16\u201319, 2001","author":"Wasilewski M.","year":"2001"},{"key":"e_1_2_1_48_2","first-page":"L\u2010739a","volume-title":"Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 14\u201317, 2003","author":"Giamarellou H.","year":"2003"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(99)00216-4"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2595-2601.2002"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.3.479"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.4.738"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2747-2751.2000"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.892-895.2002"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2225-2229.2000"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.400-404.2003"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(99)00092-9"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.1085-1088.2000"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf196"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.9.2604-2608.2001"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.10.3164-3167.2002"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00198-9"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(01)00332-7"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2000.00034-6.x"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.2.533-540.2003"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(01)00269-3"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(00)00193-0"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.1867-1874.2003"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg289"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.1875-1881.2003"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.8.2644-2645.2003"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.3022-3027.2000"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.943-949.2000"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.14.219S.35046"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.17.1517.34117"},{"key":"e_1_2_1_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(99)00090-5"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2000.6.277"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.2.665-669.2003"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.3.972-978.2003"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.2.529-532.2003"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.216-222.2003"},{"key":"e_1_2_1_82_2","first-page":"A\u2010496","volume-title":"Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 26\u201329, 1999","author":"Muralidharan G.","year":"1999"},{"key":"e_1_2_1_83_2","first-page":"A\u20101403","volume-title":"Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 27\u201330, 2002","author":"Sesoko S.","year":"2002"},{"key":"e_1_2_1_84_2","first-page":"A\u2010502","volume-title":"Program and abstracts of the 40th interscience conference on antimicrobial agents and chemotherapy, Toronto, Ontario, Canada, September 17\u201320, 2000","author":"Muralidharan G.","year":"2000"},{"key":"e_1_2_1_85_2","first-page":"A\u201022","volume-title":"Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 14\u201317, 2003","author":"Troy SM","year":"2003"},{"key":"e_1_2_1_86_2","first-page":"L\u2010738","volume-title":"Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 14\u201317, 2003","author":"Postier R.","year":"2003"},{"key":"e_1_2_1_87_2","first-page":"L\u2010739","volume-title":"Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 14\u201317, 2003","author":"Murray J.","year":"2003"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.24.1.58.34808","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.24.1.58.34808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:02:38Z","timestamp":1761066158000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.24.1.58.34808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["10.1592\/phco.24.1.58.34808"],"URL":"https:\/\/doi.org\/10.1592\/phco.24.1.58.34808","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1]]},"assertion":[{"value":"2012-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}